Senti Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity
(In thousands, except share data)
| Redeemable Convertible Preferred Stock · Common Stock · Additional Paid-in Capital · Accumulated Deficit · Total Stockholders’ Equity | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | |||||||
| Balance at December 31, 2024 | 21,157 | $25,106 | 4,829,035 | $1 | $322,782 | $(297,134) | $25,649 |
| Conversion of Series A redeemable convertible preferred stock to common stock | (21,157) | (25,106) | 21,157,000 | 2 | 25,104 | — | 25,106 |
| Issuance of common stock for vesting of restricted stock units | — | — | 17,909 | — | — | — | — |
| Vesting of early exercise of common stock options | — | — | 422 | — | 12 | — | 12 |
| Stock-based compensation | — | — | — | — | 1,204 | — | 1,204 |
| Net loss | — | — | — | — | — | (14,112) | (14,112) |
| Balance at March 31, 2025 | — | — | 26,004,366 | 3 | 349,102 | (311,246) | 37,859 |
| Issuance of common stock related to ATM, net of commissions and issuance costs | — | — | 155,840 | — | — | — | — |
| Stock-based compensation | — | — | — | — | 1,526 | — | 1,526 |
| Net loss | — | — | — | — | — | (14,733) | (14,733) |
| Balance at June 30, 2025 | — | — | 26,160,206 | 3 | 350,628 | (325,979) | 24,652 |
| Issuance of common stock related to ATM, net of commissions and issuance costs | — | — | 89,120 | — | 44 | — | 44 |
| Issuance of common stock for vesting of restricted stock units | — | — | 41,512 | — | — | — | — |
| Stock-based compensation | — | — | — | — | 1,551 | — | 1,551 |
| Net loss | — | — | — | — | — | (18,126) | (18,126) |
| Balance at September 30, 2025 | — | $— | 26,290,838 | $3 | $352,223 | $(344,105) | $8,121 |
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity — (Continued)
(In thousands, except share data)
| Redeemable Convertible Preferred Stock · Common Stock · Additional Paid-in Capital · Accumulated Deficit · Total Stockholders’ Equity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | ||||||||||
| Balance at December 31, 2023 | — | $— | 4,569,900 | $1 | $311,256 | $(244,344) | $66,913 | |||
| Vesting of early exercise of common stock options | — | — | 1,266 | — | 34 | — | 34 | |||
| Stock-based compensation | — | — | — | — | 1,258 | — | 1,258 | |||
| Net loss | — | — | — | — | — | (12,111) | (12,111) | |||
| Balance at March 31, 2024 | — | — | 4,571,166 | 1 | 312,548 | (256,455) | 56,094 | |||
| Vesting of early exercise of common stock options | — | — | 1,266 | — | 33 | — | 33 | |||
| Stock-based compensation | — | — | — | — | (776) | — | (776) | |||
| Net loss | — | — | — | — | — | (11,203) | (11,203) | |||
| Balance at June 30, 2024 | — | — | 4,572,432 | 1 | 311,805 | (267,658) | 44,148 | |||
| Vesting of early exercise of common stock options | — | — | 1,266 | — | 34 | — | 34 | |||
| Issuance of common stock for vesting of restricted stock units | — | — | 9,666 | — | — | — | — | |||
| Funds received from Chardan ChEF Instrument, net of fees | — | — | 3,593 | — | 10 | — | 10 | |||
| Stock-based compensation | — | — | — | 668 | — | 668 | ||||
| Net loss | — | — | — | — | — | (28,866) | (28,866) | |||
| Balance at September 30, 2024 | — | $— | 4,586,957 | $1 | $312,517 | $(296,524) | $15,994 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.